Xoma Technology Ltd.

Xoma (us) LLC

University of California

Novartis Ag

Musc Foundation for Research Development

Amer M Mirza

Daniel H Bedinger

Toshihiko Takeuchi

Shireen S Khan

Ajay J Narasimha

Ou Li

Kirk William Johnson

Hassan Issafras

Agnes Choppin Holmes

Rosemary J Akhurst

Linda Masat

Marina Roell

Mohammad Luqman

Mark Rubinstein

Jason Damiano

Kiranjit Kaur Ahluwalia

Raphael D Levy

Rachel A Hunt

Hoa Giang

Robyn Cotter

Lauren Schwimmer

Kristin Camfield Lind

Genevieve Nonet

Llewelyn Lao

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Antibodies that bind interleukin-2 and uses thereof

The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.

Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment

The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.

Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof

The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF&#x3b2;) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF&#x3b2;), including TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF&#x3b2; expression.

Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3

Treatment of cancer using anti-TGF-&#x3b2; and anti-PD-1 antibodies

Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-&#x3b2;

Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

TGF-beta-specific antibodies and methods of use thereof for treatment

Antibodies specific for TGF-&#x3b2;  and methods of treatment thereof

PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.

PRLR-specific antibody and uses thereof

Antibodies specific for TGF-beta and methods for treating thereof

Growing community of inventors

Berkeley, CA, United States of America

Amer M Mirza